Robert Preti, PhD, Opens the 2017 Cell & Gene Meeting on the Mesa

At this year's Cell & Gene Meeting on the Mesa, Robert Preti, PhD, Chairman of the Alliance for Regenerative Medicine and President and CEO of Hitachi Chemical Advanced Therapeutics Solutions, LLC, opened the conference with a state of the industry oveview. In his welcoming remarks, Dr. Preti discusses a robust and expanding global sector with over 800 therapeutic developers now worldwide, alongside a 24% year over year growth in on-going clincal trials.

To hear the full industry update from the Meeting on the Mesa 2017 kick-off, watch the video here:

At the 2017 Meeting on the Mesa, there were over 970 attendees over the course of the 3 day conference with over 70 presentations and interactive panels. Dr. Preti moderated an expert panel to explore a number of questions including:

• What are the benefits to going global in terms of cell therapy development and commercialization strategies?
• How are developers establishing strategies and capacity for global development and manufacturing?
• What considerations go into the choice to expand geographic reach for a product candidate? Can global strategy wait until the first commercial approval is achieved? What is the optimum timing?
• What are the pitfalls or challenges of a global strategy and how can they be avoided?

Watch the full workshop, Helping Your Cell Therapy Go Global, to hear the panelists answers to those questions:

For more information on helping your cell therapy go global, visit our Resource Center.